Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
A Phase 3 Open Label Multicenter, Randomized Study to Compare the Efficacy and Safety of the Zevalin (Ibritumomab Tiuxetan) Therapeutic Regimen Following Cyclophosphamide, Vincristine, Prednisone, and Rituximab (R-CVP) With R-CVP Alone in High-Risk Subjects With Previously Untreated CD20-Positive Follicular Non-Hodgkin's Lymphoma
Sponsor: CTI BioPharma
Terminated
Study was terminated early as per the Sponsor's decision.
This PHASE3 trial investigates Follicular Lymphoma and Lymphoma, Follicular and is currently terminated or withdrawn. CTI BioPharma leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Feb 2022 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Nov 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CTI BioPharma
- Spectrum Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .